Outcomes of Patients With Autosomal Dominant Polycystic Kidney Disease Prescribed SGLT2 Inhibitors in British Columbia: A Single-Arm Retrospective Cohort Study.

ABSTRACT:

Background

Autosomal dominant polycystic kidney disease (ADPKD) is the fourth leading cause of kidney failure in Canada and internationally. To date, patients with ADPKD have been excluded from trials of sodium-glucose cotransporter type 2 inhibitors (SGLT2i), which have been demonstrated to positively influence a wide range of kidney outcomes across the spectrum of chronic kidney disease (CKD). This exclusion was primarily due to theoretic safety concerns, particularly hastening disease progression due to vasopressin stimulation. As a result, there is a paucity of data on SGLT2i use among patients with ADPKD.

Objectives

To estimate the risk of kidney dysfunction with SGLT2i treatment among patients with ADPKD.

Design

Single-arm retrospective cohort study.

Setting

SUBMITTER: Cau A 

PROVIDER: S-EPMC12701218 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature